Krishna Vaddi, CEO at Prelude Therapeutics Inc (PRLD), bought 5,000 shares at $1.21 ($6K) on 2024-12-31, disclosed to the SEC on 2025-01-03.
Open-market purchase of $6k PRLD by CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| PRLD | BUY | 2025-03-18 | $29K | — | Filing → |
| PRLD | BUY | 2025-03-14 | $70K | — | Filing → |
| PRLD | BUY | 2025-01-02 | $12K | — | Filing → |